128 related articles for article (PubMed ID: 17284247)
1. Tumor-specific antivascular effect of TZT-1027 (Soblidotin) elucidated by magnetic resonance imaging and confocal laser scanning microscopy.
Natsume T; Watanabe J; Ogawa K; Yasumura K; Kobayashi M
Cancer Sci; 2007 Apr; 98(4):598-604. PubMed ID: 17284247
[TBL] [Abstract][Full Text] [Related]
2. Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma.
Watanabe J; Natsume T; Kobayashi M
Cancer Sci; 2006 Dec; 97(12):1410-6. PubMed ID: 16999818
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents.
Watanabe J; Natsume T; Kobayashi M
Anticancer Drugs; 2007 Sep; 18(8):905-11. PubMed ID: 17667596
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo.
Natsume T; Watanabe J; Koh Y; Fujio N; Ohe Y; Horiuchi T; Saijo N; Nishio K; Kobayashi M
Cancer Sci; 2003 Sep; 94(9):826-33. PubMed ID: 12967483
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.
Kobayashi M; Natsume T; Tamaoki S; Watanabe J; Asano H; Mikami T; Miyasaka K; Miyazaki K; Gondo M; Sakakibara K; Tsukagoshi S
Jpn J Cancer Res; 1997 Mar; 88(3):316-27. PubMed ID: 9140117
[TBL] [Abstract][Full Text] [Related]
6. TZT-1027 elucidates antitumor activity through direct cytotoxicity and selective blockade of blood supply.
Hashiguchi N; Kubota T; Koh J; Yamada Y; Saikawa Y; Otani Y; Watanabe M; Kumai K; Kitajima M; Watanabe J; Kobayashi M
Anticancer Res; 2004; 24(4):2201-8. PubMed ID: 15330161
[TBL] [Abstract][Full Text] [Related]
7. The inhibitory effect of docetaxel and p38 MAPK inhibitor on TZT-1027 (Soblidotin)-induced antivascular activity.
Watanabe J; Natsume T; Kobayashi M
Anticancer Res; 2007; 27(6B):3909-18. PubMed ID: 18225550
[TBL] [Abstract][Full Text] [Related]
8. The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo.
Akashi Y; Okamoto I; Suzuki M; Tamura K; Iwasa T; Hisada S; Satoh T; Nakagawa K; Ono K; Fukuoka M
Br J Cancer; 2007 May; 96(10):1532-9. PubMed ID: 17473826
[TBL] [Abstract][Full Text] [Related]
9. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.
Otani M; Natsume T; Watanabe JI; Kobayashi M; Murakoshi M; Mikami T; Nakayama T
Jpn J Cancer Res; 2000 Aug; 91(8):837-44. PubMed ID: 10965026
[TBL] [Abstract][Full Text] [Related]
10. [Antitumor effects of TZT-1027, a novel dolastatin 10 derivative, on human tumor xenografts in nude mice].
Fujita F; Koike M; Fujita M; Sakamoto Y; Tsukagoshi S
Gan To Kagaku Ryoho; 2000 Mar; 27(3):451-8. PubMed ID: 10740640
[TBL] [Abstract][Full Text] [Related]
11. Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs.
Natsume T; Watanabe J; Horiuchi T; Kobayashi M
Anticancer Res; 2006; 26(2A):1145-51. PubMed ID: 16619516
[TBL] [Abstract][Full Text] [Related]
12. [Activity of a novel antitumor agent, TZT-1027].
Kobayashi M; Natsume T; Watanabe J; Fujio N; Mikami T; Miyasaka K; Tsukagoshi S
Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():230P-235P. PubMed ID: 10629886
[TBL] [Abstract][Full Text] [Related]
13. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
Benakanakere I; Besch-Williford C; Schnell J; Brandt S; Ellersieck MR; Molinolo A; Hyder SM
Clin Cancer Res; 2006 Jul; 12(13):4062-71. PubMed ID: 16818706
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
15. A rat cell line derived from DMBA-induced mammary carcinoma.
Chow LW; Cheung MN; Loo WT; Guan XY
Life Sci; 2003 May; 73(1):27-40. PubMed ID: 12726884
[TBL] [Abstract][Full Text] [Related]
16. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats.
Saarinen NM; Wärri A; Dings RP; Airio M; Smeds AI; Mäkelä S
Int J Cancer; 2008 Sep; 123(5):1196-204. PubMed ID: 18528864
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of edotecarin in breast carcinoma models.
Ciomei M; Croci V; Stellari F; Amboldi N; Giavarini R; Pesenti E
Cancer Chemother Pharmacol; 2007 Jul; 60(2):229-35. PubMed ID: 17089166
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of TZT-1027 (Soblidotin).
Watanabe J; Minami M; Kobayashi M
Anticancer Res; 2006; 26(3A):1973-81. PubMed ID: 16827132
[TBL] [Abstract][Full Text] [Related]
19. Exposure of Sprague-Dawley rats to a 50-Hertz, 100-microTesla magnetic field for 27 weeks facilitates mammary tumorigenesis in the 7,12-dimethylbenz[a]-anthracene model of breast cancer.
Thun-Battersby S; Mevissen M; Löscher W
Cancer Res; 1999 Aug; 59(15):3627-33. PubMed ID: 10446973
[TBL] [Abstract][Full Text] [Related]
20. Cetirizine and thalidomide synergistically inhibit mammary tumorigenesis and angiogenesis in 7,12-dimethylbenz(a)anthracene-treated rats.
Ionov ID; Gorev NP; Roslavtseva LA; Frenkel DD
Anticancer Drugs; 2018 Nov; 29(10):956-964. PubMed ID: 30134286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
